Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination

Pol, Jonathan; Bridle, Byram W.; Lichty, Brian D.

doi:10.1007/978-1-4939-9794-7_12

Cited by 9 publications

(6 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further investigations will aim at identifying the self-antigens responsible for this cross-reactivity, among which PDC-E2 is one candidate. They will substantiate the shared immune response and validate potential targets for the formulation of immunotherapeutic strategies against CCA (e.g., cancer vaccines; Pol et al, 2019 ; Pol et al, 2018 ; Pol et al, 2020a ; Pol et al, 2020b ; Pol et al, 2014 ).…”

Section: Discussionmentioning

confidence: 92%

Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma

Paillet

Plantureux

Lévesque

et al. 2021

Journal of Experimental Medicine

Self Cite

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) results from the malignant transformation of cholangiocytes. Primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) are chronic diseases in which cholangiocytes are primarily damaged. Although PSC is an inflammatory condition predisposing to CCA, CCA is almost never found in the autoimmune context of PBC. Here, we hypothesized that PBC might favor CCA immunosurveillance. In preclinical murine models of cholangitis challenged with syngeneic CCA, PBC (but not PSC) reduced the frequency of CCA development and delayed tumor growth kinetics. This PBC-related effect appeared specific to CCA as it was not observed against other cancers, including hepatocellular carcinoma. The protective effect of PBC was relying on type 1 and type 2 T cell responses and, to a lesser extent, on B cells. Single-cell TCR/RNA sequencing revealed the existence of TCR clonotypes shared between the liver and CCA tumor of a PBC host. Altogether, these results evidence a mechanistic overlapping between autoimmunity and cancer immunosurveillance in the biliary tract.

show abstract

Section: Discussionmentioning

confidence: 92%

Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma

Paillet

Plantureux

Lévesque

et al. 2021

Journal of Experimental Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, it was recently shown that dendritic cell-mediated anti-tumor immunity is compromised by cancer cells undergoing ferroptosis [ 116 ]. To respond to the tumor antigens, antigen-presenting cells (APCs) catch TAAs and neoantigens released by tumor cells, and then activate tumor-specific T lymphocytes [ 117 , 118 ]. On the surface of tumor cells infected with OVs, there are virus-specific antigens, which help in their elimination by antiviral T lymphocytes [ 119 ].…”

Section: Mechanisms Of Oncolytic Virotherapymentioning

confidence: 99%

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

et al. 2023

View full text Add to dashboard Cite

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no damage to normal cells in the process. Because of their specific features, such as, the ability to induce immunogenic cell death and to contain curative transgenes in their genomes, OVs have attracted attention as candidates to be utilized in cooperation with immunotherapies for cancer treatment. This treatment takes advantage of most tumor cells' inherent tendency to be infected by certain OVs and both innate and adaptive immune responses are elicited by OV infection and oncolysis. OVs can also modulate tumor microenvironment and boost anti-tumor immune responses. Mesenchymal stem cells (MSC) are gathering interest as promising anti-cancer treatments with the ability to address a wide range of cancers. MSCs exhibit tumor-trophic migration characteristics, allowing them to be used as delivery vehicles for successful, targeted treatment of isolated tumors and metastatic malignancies. Preclinical and clinical research were reviewed in this study to discuss using MSC-released OVs as a novel method for the treatment of cancer.

show abstract

“…Direct oncolysis activity of OVs is the first stimulus of the immune response in the TME [ 92 ]. Overexpression of surface receptors such as CD46, CD54, CD155, CD55, and integrins enhances OVs’ preferable entry to tumor cells [ 93 , 94 , 95 , 96 , 97 ].…”

Section: Oncolytic Virus Effects On Tmementioning

confidence: 99%

“…Tumor cells have defects in antiviral pathways such as IFN-I, PKR, and JAK-STAT, resulting in the survival and proliferation of OVs, specifically in tumor cells [ 99 , 100 , 101 ]. Lysis of OV-infected cells releases a very diverse TAAs that prime immune cells to induce a local and systemic vaccination against the released TAAs [ 92 ]. While many cancer immunotherapies depend on identifying and targeting TAAs (one or several limited TAAs), OVT can vaccinate patients against the entire TAA and TAN treasure of cancer through a phenomenon called antigen/epitope spreading.…”

Section: Oncolytic Virus Effects On Tmementioning

confidence: 99%

Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

Jin

Liu

et al. 2021

Cancers

View full text Add to dashboard Cite

Oncolytic virotherapy (OVT) is a promising approach in cancer immunotherapy. Oncolytic viruses (OVs) could be applied in cancer immunotherapy without in-depth knowledge of tumor antigens. The capability of genetic modification makes OVs exciting therapeutic tools with a high potential for manipulation. Improving efficacy, employing immunostimulatory elements, changing the immunosuppressive tumor microenvironment (TME) to inflammatory TME, optimizing their delivery system, and increasing the safety are the main areas of OVs manipulations. Recently, the reciprocal interaction of OVs and TME has become a hot topic for investigators to enhance the efficacy of OVT with less off-target adverse events. Current investigations suggest that the main application of OVT is to provoke the antitumor immune response in the TME, which synergize the effects of other immunotherapies such as immune-checkpoint blockers and adoptive cell therapy. In this review, we focused on the effects of OVs on the TME and antitumor immune responses. Furthermore, OVT challenges, including its moderate efficiency, safety concerns, and delivery strategies, along with recent achievements to overcome challenges, are thoroughly discussed.

show abstract

Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination

Cited by 9 publications

References 69 publications

Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma

Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma

Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment

Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements

Contact Info

Product

Resources

About